A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2018
Price : $35 *
At a glance
- Drugs Ribociclib (Primary) ; Aromatase inhibitors
- Indications Advanced breast cancer
- Focus Adverse reactions
- 10 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Jun 2018 Planned End Date changed from 1 May 2020 to 1 Jun 2020.
- 20 Jun 2018 Planned primary completion date changed from 1 May 2020 to 1 Jun 2020.